Intuitive Surgical, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. Although the request references 2022 Q4, this filing is an annual report and the figures below are primarily full-year results, not standalone fourth-quarter results. Intuitive develops and sells da Vinci surgical systems and the Ion endoluminal system, with recurring revenue from instruments, accessories, and services.
Financial and operating performance
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Total revenue | $6.22 billion | $5.71 billion | +9% |
| Gross profit / margin | $4.20 billion / 67.4% | $3.96 billion / 69.3% | Margin down 1.9 percentage points |
| Operating income / margin | $1.58 billion / 25.3% | $1.82 billion / 31.9% | Income down 13% |
| Net income attributable to Intuitive | $1.32 billion | $1.70 billion | Down 22% |
| Diluted EPS | $3.65 | $4.66 | Down 22% |
| Cash from operations | $1.49 billion | $2.09 billion | Down 29% |
- Instruments and accessories revenue was $3.52 billion, up 13%; service revenue was $1.02 billion, up 12%; systems revenue was $1.68 billion, down 1%. Recurring revenue reached $4.92 billion, or 79% of total revenue, versus 75% in 2021.
- Da Vinci procedures increased 18% to approximately 1.875 million; Ion biopsies rose to approximately 23,500 from 7,400. The da Vinci installed base grew 12% to 7,544 systems; Ion’s rose to 321. Da Vinci placements declined 6% to 1,264.
- Operating expenses rose 23% to $2.62 billion, including SG&A up 19% and R&D up 31%. Management cited higher headcount, compensation, infrastructure, litigation, development initiatives, freight, and materials costs.
- Cash, cash equivalents, and investments totaled $6.74 billion at year-end, down from $8.62 billion. Current assets were $6.25 billion and current liabilities $1.42 billion. The balance sheet presents no borrowings as a separate debt line; total liabilities were $1.86 billion.
- FY2022 capital expenditures were $532 million. The company repurchased 11.2 million shares for $2.61 billion. Inventory increased $306 million on the balance sheet to $893 million; operating cash flow was also affected by working-capital uses, including the inventory build.
Material changes and drivers
- Revenue growth reflected procedure expansion and larger installed bases, especially in instruments and accessories and service. Procedure growth was strongest in U.S. general surgery and OUS urology and general surgery.
- Profitability weakened despite revenue growth: gross margin fell from 69.3% to 67.4%, and operating margin from 31.9% to 25.3%. Management attributed margin pressure to higher fixed overhead, freight and materials costs, foreign exchange, and lower da Vinci system average selling prices.
- Systems revenue was pressured by fewer placements, lower sales-type lease revenue and lease buyouts, lower average selling prices, and a higher share of operating-lease placements; higher operating-lease revenue and Ion placements partly offset the decline.
- Foreign exchange reduced OUS revenue by $138 million versus 2021. Net unrealized losses on available-for-sale investments, net of tax, were $154.2 million at year-end, compared with $16.0 million in 2021.
- Income tax expense increased to $262 million from $162 million; the effective tax rate was 16.3% versus 8.6%. The comparison reflects, among other items, lower excess tax benefits from equity awards, new U.S. R&D capitalization rules, and a 2021 one-time Swiss deferred-tax benefit.
Outlook, risks, contingencies, and unusual items
- Outlook: No specific revenue or earnings guidance is provided in the supplied filing text. Management expects substantial and increasing R&D investment. It forecasts 2023 capital expenditures of $800 million to $1 billion, with more than half facility-related, funded from operating cash flow.
- Management reported a softer U.S. capital pipeline and expects capital-equipment demand to remain affected by hospital budget constraints, inflation, higher interest rates, staffing shortages, and macroeconomic uncertainty. It also cited ongoing component and logistics constraints, including semiconductor shortages, but said these had not materially impaired 2022 results or deliveries.
- COVID-19 resurgences disrupted procedures during 2022, particularly in China in Q4; deferred diagnoses and elective procedures may affect recovery timing. The company cautions that procedure volumes and system placements are seasonal and may fluctuate.
- On or about February 10, 2023, the company planned a voluntary field action for a defect in a third-party component in certain da Vinci arms. Customers were advised to stop using approximately 109 da Vinci X and Xi systems pending replacement. No related adverse events had been reported; the company did not expect a material financial impact.
- Legal matters include product-liability cases for which potential losses in excess of accrued amounts could not be estimated, antitrust litigation concerning instrument service and repair, and a $10 million patent verdict for Rex Medical that Intuitive intended to appeal. FY2022 pre-tax litigation charges were $28.1 million. The Restore litigation was settled in January 2023 with an immaterial FY2022 financial-statement impact.
- Additional risks include reimbursement and hospital affordability, competition, regulatory approvals and EU MDR certification, supplier concentration, cybersecurity and privacy, foreign exchange, China system quotas and provincial price limits, and reliance on customer adoption and training. The company noted that Hunan’s limits on charges for robotic procedures had materially reduced procedures there; similar limits were announced in Hainan.
- Auditor PwC issued unqualified opinions on the financial statements and internal control over financial reporting; management and the auditor concluded controls were effective at year-end. The auditor identified system-sale standalone selling price estimates as a critical audit matter.
Important facts for investors to verify
- Whether procedure growth and recurring revenue can offset slower system placements and continued pressure on gross and operating margins.
- Whether hospital capital budgets, staffing conditions, and supply availability improve, and how 2023 placements compare with the 2022 decline.
- Actual 2023 capital spending versus the $800 million to $1 billion outlook, and the resulting effect on cash and investment balances.
- Progress and financial exposure in product-liability, antitrust, and patent matters, including the appeal of the Rex Medical verdict and the da Vinci arm field action.
- Effects of China’s system quota, COVID-related procedure disruption, and provincial robotic-surgery price limits, alongside foreign-exchange movements.
- How the Extended Use Program and lower instrument prices affect revenue per procedure, customer adoption, and margins.